Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc..
November 20, 2021
Share
Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR) on November 21, 2021. The rights are to develop, manufacture and commercialize the investigational antibody obexelimab. Under the terms of the new agreement, Zenas will issue to Xencor a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor?s total equity in Zenas would be 15% of its fully diluted capitalization following the closing of Zenas? next round of equity financing, subject to certain requirements. Xencor is also eligible to receive up to?$480 million?based on the achievement of certain clinical development, regulatory and commercialization milestones and is eligible to receive tiered, mid-single digit to mid-teen percent royalties upon commercialization of obexelimab, dependent on geography.
Zenas BioPharma Limited completed the acquisition of Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.